Zacks Research Lifts Earnings Estimates for Editas Medicine

Editas Medicine, Inc. (NASDAQ:EDIT) – Equities researchers at Zacks Research raised their Q3 2026 EPS estimates for shares of Editas Medicine in a note issued to investors on Wednesday, August 26th. Zacks Research analyst Team now forecasts that the company will earn ($0.25) per share for the quarter, up from their prior forecast of ($0.34). The consensus estimate for Editas Medicine’s current full-year earnings is ($0.85) per share. Zacks Research also issued estimates for Editas Medicine’s Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.90) EPS, Q1 2027 earnings at ($0.28) EPS, Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.29) EPS, Q4 2027 earnings at ($0.30) EPS, FY2027 earnings at ($1.16) EPS, Q1 2028 earnings at ($0.33) EPS, Q2 2028 earnings at ($0.34) EPS and FY2028 earnings at ($1.34) EPS.

Several other equities analysts have also issued reports on EDIT. TD Cowen reiterated a “buy” rating on shares of Editas Medicine in a report on Wednesday, May 27th. LADENBURG THALM/SH SH assumed coverage on Editas Medicine in a research note on Tuesday, August 18th. They issued a “buy” rating and a $6.00 price target on the stock. Weiss Ratings raised Editas Medicine from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Chardan Capital boosted their target price on Editas Medicine from $3.50 to $4.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Editas Medicine has an average rating of “Moderate Buy” and a consensus target price of $5.50.

Editas Medicine Stock Performance

Shares of EDIT opened at $3.30 on Friday. The stock has a market cap of $506.81 million, a PE ratio of -4.40 and a beta of 2.14. Editas Medicine has a fifty-two week low of $1.66 and a fifty-two week high of $4.54. The firm’s 50-day simple moving average is $2.99 and its two-hundred day simple moving average is $2.74.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.12. Editas Medicine had a negative net margin of 157.32% and a negative return on equity of 196.63%. The company had revenue of $11.89 million during the quarter, compared to analysts’ expectations of $2.85 million.

Institutional Trading of Editas Medicine

A number of large investors have recently made changes to their positions in EDIT. BlackRock Inc. purchased a new position in shares of Editas Medicine during the second quarter valued at approximately $34,312,000. ADAR1 Capital Management LLC purchased a new stake in Editas Medicine in the second quarter worth approximately $28,800,000. Renaissance Technologies LLC grew its position in Editas Medicine by 138.0% in the 4th quarter. Renaissance Technologies LLC now owns 3,039,778 shares of the company’s stock worth $6,232,000 after purchasing an additional 1,762,378 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Editas Medicine by 122.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock valued at $3,016,000 after buying an additional 1,430,000 shares during the last quarter. Finally, Seven Fleet Capital Management LP purchased a new stake in Editas Medicine during the 2nd quarter valued at $4,310,820,000. 71.90% of the stock is currently owned by institutional investors.

Insider Transactions at Editas Medicine

In other Editas Medicine news, CEO Gilmore Neil O’neill sold 15,380 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $2.70, for a total transaction of $41,526.00. Following the transaction, the chief executive officer owned 248,313 shares in the company, valued at approximately $670,445.10. This represents a 5.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 21,503 shares of company stock worth $57,910. 3.10% of the stock is currently owned by corporate insiders.

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.